Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.54 |
| ▸ | LATS1 | O95835 | 5/20 | 0.51 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759308 | 0.85 | CACNA1H (0.51) | LATS1LATS2CACNA1HCACNA1BCACNA1C | |
| SCHEMBL15597730 | 0.85 | TNKS2 (0.53) | ALDH1A1PARP1 | |
| SCHEMBL4085766 | 0.82 | CACNA1H (0.54) | LATS1LATS2CACNA1HCACNA1BCACNA1C | |
| SCHEMBL38662207 | 0.82 | CACNA1H (0.54) | LATS1LATS2CACNA1HCACNA1BCACNA1C | |
| SCHEMBL24807720 | 0.81 | LMNA (0.50) | CACNA1HCACNA1BCACNA1CALDH1A1 | |
| SCHEMBL29893686 | 0.77 | LATS1 (0.53) | LATS1LATS2NAMPT | |
| SCHEMBL6297783 | 0.73 | BCHE (0.65) | CACNA1HCACNA1BCACNA1CALDH1A1 | |
| SCHEMBL14550634 | 0.73 | BCHE (0.43) | CACNA1HCACNA1BCACNA1CNAMPTPARP1 | |
| SCHEMBL17710780 | 0.73 | KDM4C (0.68) | KDM4CKDM5AALDH1A1 | |
| SCHEMBL3518208 | 0.73 | BCHE (0.42) | CACNA1HCACNA1BCACNA1CALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022204452-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098872-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | KDM4C 3045/4885LATS1 1576/4885LATS2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.